Axil Capital | Venture Capital

top of page

ENGLISH

日本語

Top

About

Team

Portfolio

Contact

Axil Capital is a venture capital firm based in Tokyo, Japan, specializing in biomedical & healthcare technology investments, with emphasis on supporting the growth of early-stage ventures by leveraging our global network and resources.

Axil Recent News (EN)

Axil Capital's Past News

Portfolio Recent News (EN)

Portfolio Companies' Recent News

Nov 8, 2023

Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology.

Oct 19, 2023

The results of the joint research between Cranebio and Unicharm were distributed as a press release.

Oct 6, 2023

Cellusion was selected for the "Capital Investment Support Program for Breakthrough Business Promotion".

Oct 4, 2023

Cranebio has raised a total of 250 million yen through a Series A round.

Sep 11, 2023

United Immunity announced completion of fundraising and grant approval.

Sep 5, 2023

Techsomed announces FDA Clearance for Ablation Treatment Planning and Confirmation Software.

Aug 31, 2023

Jolly Good and Otsuka Pharmaceutical Launch New VR Employment Support Services! The SST-VR program "FACEDUO" is now expanding to vocational support centers and sheltered workshops.

Aug 21, 2023

Suono Bio has received an exclusive patent option from the Massachusetts Institute of Technology (MIT) for RoboCap.

Aug 8, 2023

Cellusion received MEXT Minister’s Award under the Award for Academic Startups 2023.

Jul 31, 2023

Japan's Minister of Health, Labor and Welfare experienced the employment support VR of Jolly Good.

Jul 25, 2023

Perseus Proteomics presented an interim report of the PPMX-T003 clinical trial at The 13th JSH International Symposium 2023

Jul 20, 2023

Suono Bio Reports Encouraging Results From a First in Human (FiH) Study of Its Ultrasound Mediated Drug Delivery Platform.

Jul 5, 2023

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Appli-cation for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer.

Jun 26, 2023

Techsomed Announces Field Evaluation of its image guided ablation therapy software using GE HealthCare LOGIQ™ ultrasound systems at top US clinical sites.

Jun 20, 2023

Dr. Taku Kambayashi, founder of Abrax Japan, appeared on NTV's "Learning with Kazu-Laser.

JUn 19, 2023

Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients.

Jun 7, 2023

Cellusion raises 2.83 Billion Yen (21 Million USD) in Series C Round.

May 24, 2023

Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial.

May 15, 2023

Luca Science gave a lecture at the Japan Society of Obstetrics and Gynecology (JSOG) and the presenter, Dr. Yosuke Matsumiya, received the JSOG Congress Award.

May 15, 2023

Perseus Proteomics reported that a Phase I study of PPMX-T003 confirmed the safety and efficacy of the drug in the first three patients treated with the drug.

Apr 19, 2023

Allgenesis Announces Last Patient Enrolled in the Phase 2a Trial Evaluating the Safety and Efficacy of AG-73305 in Diabetic Macular Edema (DME) Patients.

Apr 7, 2023

Himuka AM Pharma has completed a Phase I clinical trial of HM201 in Australia.

Apr 3, 2023

Cranebio presented at a conference on the development of rapid water quality testing in collaboration with Metawater, Co., Ltd.

Mar 31, 2023

Perseus Proteomics Completes PMDA Investigation of Aggressive NK Cell Leukemia Clinical Trial Plan Notification.

Mar 31, 2023

Ricoh Biomedical Startup Fund has decided to invest in United Immunity.

Mar 30, 2023

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC.

Mar 23, 2023

Jolly Good jointly developed medical VR with Harvard University Hospital to enter the U.S. market.

Mar 16, 2023

United Immunity has published an academic paper on UI-201.

Mar 15, 2023

LUCA Science was selected as one of the 2023 Deep Tech Top 10 by Forbes Japan magazine.

Feb 17, 2023

Suono Bio announces Formulation-Agnostic Platform for the delivery of RNA therapeutics.

Jan 30, 2023

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors.

Jan 4, 2023

An article on Perseus' Phase I study of PPMX-T003 in healthy subjects was published online in Clinical Pharmacology in Drug Development.

Jan 4, 2023

Suono Bio announces first patient dosed with its SuonoCalm™ Platform.

Portfolio Companies' Past News

【 Head Office 】

Nittochi Nishi-shinbashi Bldg. 7F
1-11-4 Nishi-shinbashi Minato-ku, Tokyo 105-0003, Japan

【 Technology & Innovation Center 】

GLOBAL LIFESCIENCE HUB, Nihombashi Muromachi Mitsui Tower 7F
3-2 Nihombashi Muromachi, Chuo-ku, Tokyo 103-0022

© Axil Capital All Rights Reserved

bottom of page